scholarly journals Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

The Prostate ◽  
2021 ◽  
Author(s):  
Caroline E. Nunes‐Xavier ◽  
Wanja Kildal ◽  
Andreas Kleppe ◽  
Håvard E. Danielsen ◽  
Håkon Wæhre ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Protein Expression ◽  
Immune Checkpoint ◽  
Receptor Status ◽  
Poor Outcome

Androgen receptor status of lymph node metastases from prostate cancer

The Prostate ◽  
1996 ◽  
Vol 28 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Alfred Hobisch ◽  
Zoran Culig ◽  
Christian Radmayr ◽  
Georg Bartsch ◽  
Helmut Klocker ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Lymph Node Metastases ◽  
Receptor Status ◽  
Node Metastases

Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters

The Prostate ◽  
2016 ◽  
Vol 77 (2) ◽  
pp. 222-233 ◽  
Author(s):  
Hideo Otsuki ◽  
Toru Kimura ◽  
Takashi Yamaga ◽  
Takeo Kosaka ◽  
Jun-ichi Suehiro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Receptor Status

Breast cancer in Irish families with Lynch syndrome.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 413-413
Author(s):  
E. J. Jordan ◽  
M. P. Farrell ◽  
R. M. Clarke ◽  
M. R. Kell ◽  
J. A. McCaffrey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lynch Syndrome ◽  
Protein Expression ◽  
Mismatch Repair ◽  
Hormone Receptor ◽  
Hormone Receptor Status ◽  
Breast Cancer Tissue ◽  
Cancer Tissue ◽  
Receptor Status

413 Background: Breast cancer is not a recognised malignant manifestation of Lynch Syndrome which includes colorectal, endometrial, gastric, ovarian and upper urinary tract tumours. In this study we report the prevalence of breast cancer in Irish Lynch Syndrome families and determine immunohistochemical expression of mismatch repair proteins (MMR) in available breast cancer tissue. Methods: Breast cancer prevalence was determined among Lynch Syndrome kindreds from two institutions in Ireland, and a genotype phenotype correlation was investigated. One kindred was omitted due to the presence of a biallelic MMR and BRCA1 mutation. The clinicopathological data that was collected on breast cancer cases included age of onset, morphology, and hormone receptor status. Immunohistochemical staining was performed for MLH1, MSH2, MSH6, and PMS2 on all available breast cancer tissue from affected individuals. Results: The distribution of MMR mutations seen in 16 pedigrees was as follows; MLH1 (n=5), MSH2 (7), MSH6 (3), PMS2 (1). Sixty cases of colorectal cancer and 14 cases of endometrial cancer were seen. Seven breast cancers (5 invasive ductal and 2 invasive lobular cancers) and 1 case of ductal carcinoma in situ were reported in 7 pedigrees. This compared with 4 cases of prostate cancer. Six MSH2 mutations and 1 MSH6 mutation were identified in the 7 Lynch syndrome kindreds. Median age of breast cancer diagnosis was 49 years (range 38-57). Hormone receptor status is available on 3 breast cancer cases at time of abstract submission; all were ER positive and HER 2 negative. All cases had grade 2 or 3 tumours. Final results of immunohistochemistry for mismatch repair protein expression on breast cancer samples are pending and will be reported at the meeting. One breast cancer has been tested to date and demonstrated loss of MSH2 protein expression in an individual carrying an MSH2 mutation. Conclusions: Breast cancer occurred at an early age and was more common than prostate cancer in Irish Lynch Syndrome pedigrees. All reported breast cancer cases were in kindreds with MSH2 or MSH6 mutations. Enhanced breast cancer screening may be warranted in certain Lynch Syndrome kindreds.

scholarly journals Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis

2016 ◽  
Vol 20 (1) ◽  
pp. 28-35 ◽  
Author(s):  
B Benzon ◽  
S G Zhao ◽  
M C Haffner ◽  
M Takhar ◽  
N Erho ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Poor Outcome ◽  
Immune Pathways

Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer

2017 ◽  
Vol 99 (2) ◽  
pp. 222-228 ◽  
Author(s):  
Filip Poelaert ◽  
Candy Kumps ◽  
Nicolaas Lumen ◽  
Stephanie Verschuere ◽  
Louis Libbrecht ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Protein Expression ◽  
Copy Number ◽  
Receptor Gene ◽  
Gene Copy Number ◽  
Androgen Receptor Gene ◽  
Gene Copy ◽  
Treatment Naïve

Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer

2003 ◽  
Vol 170 (5) ◽  
pp. 1817-1821 ◽  
Author(s):  
O. HARRIS FORD ◽  
CHRISTOPHER W. GREGORY ◽  
DESOK KIM ◽  
ANDREW B. SMITHERMAN ◽  
JAMES L. MOHLER
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Protein Expression ◽  
Gene Amplification ◽  
Receptor Gene ◽  
Androgen Receptor Gene ◽  
Recurrent Prostate Cancer

GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer

2010 ◽  
Vol 223 (1) ◽  
pp. 81-87 ◽  
Author(s):  
Shaun S Tan ◽  
Imran Ahmad ◽  
Haley L Bennett ◽  
Lukram Singh ◽  
Colin Nixon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Receptor Status ◽  
Castrate Resistant Prostate Cancer ◽  
Client Proteins ◽  
Castrate Resistant

scholarly journals Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients

Oncotarget ◽  
2016 ◽  
Vol 8 (3) ◽  
pp. 4875-4887 ◽  
Author(s):  
SC Patek ◽  
JM Willder ◽  
JS Heng ◽  
B Taylor ◽  
PG Horgan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Receptor Phosphorylation ◽  
Poor Outcome

scholarly journals The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Filip Poelaert ◽  
Charles Van Praet ◽  
Anne-Sophie Beerens ◽  
Gert De Meerleer ◽  
Valérie Fonteyne ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Protein Expression ◽  
Steroid Receptors ◽  
Clinical Information ◽  
Progression Free Survival ◽  
Receptor Expression ◽  
Clinical Relapse ◽  
Gleason Pattern

The androgen receptor (AR) and its signaling pathway play an important role in the development and progression of prostate cancer (PCa). In the setting of primary treatment of PCa with radiotherapy (RT), where the AR can be expected to be of more importance, studies evaluating the AR expression are lacking. The goal of this research is to evaluate AR protein expression in hormone-naive PCa patients treated by RT and investigate its possible prognostic role. Primary biopsy samples of 18 patients treated with primary RT were analyzed including the corresponding clinical information. AR protein expression of the tumor epithelium (with highest Gleason pattern) and the surrounding stroma was quantified using the Quick score for steroid receptors. The differential expression between epithelium and stroma, respectively, between tumor and normal tissue (ΔTumor − ΔBenign >2 versus ≤2), was predictive for clinical progression-free survival in the biopsy samples (P= 0.014). Preliminary results of this research show already a promising role of differential AR expression in predicting clinical relapse after PCa treatment with primary EBRT. Further research is needed to validate these findings. Hopefully this can lead to a better understanding of PCa evolution and eventually lead to better therapy strategies.

Sign in / Sign up

Export Citation Format

Share Document